Loading clinical trials...
Loading clinical trials...
Phase 1/2 Study of VELCADE (Bortezomib), Nipent (Pentostatin), and Rituxan (Rituximab) (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Conditions
Interventions
MTD of Velcade, Nipent and Rituxan established in Part 1
Locations
1
United States
LSU - Shreveport Health Sciences Center, Feist-Weiller Cancer Center
Shreveport, Louisiana, United States
Start Date
May 1, 2010
Primary Completion Date
October 1, 2014
Completion Date
October 1, 2014
Last Updated
September 1, 2020
NCT06263491
NCT06337318
NCT05529069
NCT05006716
NCT06026319
NCT07128641
Lead Sponsor
Louisiana State University Health Sciences Center Shreveport
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions